تقييم المؤشرات الحيوية لوظائف الكلى لدى المرضى اليمنيين المصابين بثلاسيميا بيتا المعتمدين على نقل الدم

[1] Farmakis D, Porter J, Taher A, Cappellini MD, Angastiniotis M, Eleftheriou A, et al. 2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia. HemaSphere. 2022;6(8):e732. http://dx.doi.org/10.1097/HS9.0000000000000732 DOI: https://doi.org/10.1097/HS9.0000000000000732

[2] Demosthenous C, Vlachaki E, Apostolou C, Eleftheriou P, Kotsiafti A, Vetsiou E, et al. Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology. 2019;24(1):426–38. https://doi.org/10.1080/16078454.2019.1599096 DOI: https://doi.org/10.1080/16078454.2019.1599096

[3] Arian M, Oghazian MB, Nour El dine MH, Valinejad A, Badiee Z, Soleimani M, Sahebkar A. Biochemical markers of early renal dysfunction in patients with β-thalassemia major: a systematic review and meta-analysis. Current Medicinal Chemistry. 2025;32(13):2572-97. https://doi.org/10.2174/0109298673250805230922054406 DOI: https://doi.org/10.2174/0109298673250805230922054406

[4] Hashemieh M. Early detection of renal dysfunction in β thalassemia with focus on novel biomarkers. Iranian Journal of Pediatric Hematology & Oncology. 2020;10(1):57–68. DOI: https://doi.org/10.18502/ijpho.v10i1.2170

[5] Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, et al. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Blood Cells, Molecules, and Diseases. 2024;107:102859. https://doi.org/10.1016/j.bcmd.2024.102859 DOI: https://doi.org/10.1016/j.bcmd.2024.102859

[6] Al-Nood H. Thalassemia trait in outpatient clinics of Sana'a city, Yemen. Hemoglobin. 2009;33(3-4):242-46. https://doi.org/10.1080/03630260903039594 DOI: https://doi.org/10.1080/03630260903039594

[7] Banafa AM, Al-Awar MS, Ahmed AAY, Edrees WH, Alyafrosi OAH, Y. Haemosiderosis, liver and renal diseases among thalassemia patients in Sana’a city – Yemen. Al-Razi University Journal of Medical Sciences. 2022;6(2):1–10. https://doi.org/10.51610/rujms6.2.2022.142 DOI: https://doi.org/10.51610/rujms6.2.2022.142

[8] Tantawy AAG, El Bablawy N, Adly AAM, Ebeid FSE. Early predictors of renal dysfunction in Egyptian patients with β-thalassemia major and intermedia. Mediterranean Journal of Hematology and Infectious Diseases. 2014;6(1):e2014057. DOI: https://doi.org/10.4084/mjhid.2014.057

[9] Pierce CB, Muñoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ. Age-and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney International. 2021;99(4):948-56. https://doi.org/10.1016/j.kint.2020.10.047 DOI: https://doi.org/10.1016/j.kint.2020.10.047

[10] Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, et al. New creatinine-and cystatin C–based equations to estimate GFR without race. The New England Journal of Medicine. 2021;385(19):1737-49. https://doi.org/10.1056/NEJMoa2102953 DOI: https://doi.org/10.1056/NEJMoa2102953

[11] Elsayed ME, Sharif MU, Stack AG. Chapter four - transferrin saturation: a body iron biomarker. Advances in Clinical Chemistry. 2016;75:71-97. https://doi.org/10.1016/bs.acc.2016.03.002 DOI: https://doi.org/10.1016/bs.acc.2016.03.002

[12] Cao A, Galanello R. Beta-thalassemia. Genetics in Medicine. 2010;12(2):61–76. https://doi.org/10.1097/GIM.0b013e3181cd68ed DOI: https://doi.org/10.1097/GIM.0b013e3181cd68ed

[13] Sadiq IZ, Abubakar FS, Usman HS, Abdullahi AD, Ibrahim B, Kastayal BS, Ibrahim M, Hassan HA. Thalassemia: pathophysiology, diagnosis, and advances in treatment. Thalassemia Reports. 2024;14(4):81–102. https://doi.org/10.3390/thalassrep14040010 DOI: https://doi.org/10.3390/thalassrep14040010

[14] Cazzola M. Ineffective erythropoiesis and its treatment. Blood. 2022;139(16):2460–70. https://doi.org/10.1182/blood.2021011045 DOI: https://doi.org/10.1182/blood.2021011045

[15] Lin S, Zheng Y, Chen M, Xu L, Huang H. The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia. Frontiers in Physiology. 2024;15:1–10. https://doi.org/10.3389/fphys.2024.1346173 DOI: https://doi.org/10.3389/fphys.2024.1346173

[16] Basu S, Rahaman M, Dolai TK, Shukla PC, Chakravorty N. Understanding the intricacies of iron overload associated with β-thalassemia: a comprehensive review. Thalassemia Reports. 2023;13(3):179–94. https://doi.org/10.3390/thalassrep13030017 DOI: https://doi.org/10.3390/thalassrep13030017

[17] Karim MF, Ismail M, Hasan AKMM, Shekhar HU. Hematological and biochemical status of beta-thalassemia major patients in Bangladesh: a comparative analysis. International Journal of Hematology-Oncology and Stem Cell Research. 2016;10(1):7-12.

[18] Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with β-thalassemia major and thalassemia intermedia. Pediatric Nephrology. 2008;23(10):1847-51. https://doi.org/10.1007/s00467-008-0897-8 DOI: https://doi.org/10.1007/s00467-008-0897-8

[19] El-Hawy MA, Allam ET, Shashin HAEM, El-Haroun MS. Urinary biomarkers of early kidney injury in children with beta-thalassemia. Pediatric Hematology/Oncology and Immunopathology. 2023;22(4):90-5. https://doi.org/10.24287/1726-1708-2023-22-4-90-95 DOI: https://doi.org/10.24287/1726-1708-2023-22-4-90-95

[20] Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Annals of Hematology. 2016;95(3):375-81. https://doi.org/10.1007/s00277-015-2561-2 DOI: https://doi.org/10.1007/s00277-015-2561-2

[21] Thongsaen P, Tonsawan P, Wanitpongpun C, Lanamtieng T, Phiphitaporn P, Teawtrakul N. Clinical features and risk factors of renal dysfunctions in thalassemic patients. International Urology and Nephrology. 2023;55(7):1779-85. https://doi.org/10.1007/s11255-023-03506-3 DOI: https://doi.org/10.1007/s11255-023-03506-3

[22] Hashemieh M. Comparative evaluation of glomerular and tubular function abnormalities in patients with different forms of β-thalassemia, an emerging concern. Journal of Pediatric Nephrology. 2019;7(2):1-7. https://doi.org/10.22037/jpn.v7i2.27833

[23] Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T. A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatric Hematology and Oncology. 2013;30(8):748-54. https://doi.org/10.3109/08880018.2013.823470 DOI: https://doi.org/10.3109/08880018.2013.823470

[24] Musallam KM, Taher AT. Mechanisms of renal disease in β-thalassemia. Journal of the American Society of Nephrology. 2012;23(8):1299-302. http://doi.org/10.1681/ASN.2011111070 DOI: https://doi.org/10.1681/ASN.2011111070

[25] Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood Reviews. 2010;24(6):239-44. https://doi.org/10.1016/j.blre.2010.08.004 DOI: https://doi.org/10.1016/j.blre.2010.08.004

[26] Al-kenany RK, Al-Janabi GG, Al-Saedi SR. Biochemical study of some parameters in patients with b-thalassemia in Karbala city. Indian Journal of Forensic Medicine & Toxicology. 2021;15(2):3353-8. DOI: https://doi.org/10.37506/ijfmt.v15i2.14893

[27] Tellioglu AM, Karadas S, Bilgin MD, Caliskan SO. Assessment of body composition with bioelectrical impadence analysis in thalassemia major patients. Journal of Experimental and Clinical Medicine. 2017;34(2):93-7.

[28] Khandker SS, Jannat N, Sarkar D, Pranto AH, Hoque IA, Zaman J, Nizam Uddin M, Suez E. Association between glomerular filtration rate and β-thalassemia major: a systematic review and meta-analysis. Thalassemia Reports. 2023;13(3):195-205. https://doi.org/10.3390/thalassrep13030018 DOI: https://doi.org/10.3390/thalassrep13030018

[29] Hassanein N, Thabet MAE, Maarouf D, Mikhail N. Study of uric acid excretion in children with beta-thalassemia major attending Alexandria University Children’s Hospital. Alexandria Journal of Pediatrics. 2022;35(1):33-9. https://doi.org/10.4103/ajop.ajop_6_22 DOI: https://doi.org/10.4103/ajop.ajop_6_22

[30] Milo G, Nevo RFG, Pazgal I, Gafter-Gvili A, Shpilberg O, Gafter U, Erman A, Stark P. GFR in patients with β-thalassemia major. Clinical Journal of the American Society of Nephrology. 2015;10(8):1350-6. https://doi.org/10.2215/CJN.12181214 DOI: https://doi.org/10.2215/CJN.12181214

[31] Khawaji MM, Hazzazi AA, Ageeli MH, Mawkili YH, Darbashi AH, Kathiyah AMAA, Humedi RA. Clinical and hematological features among β-thalassemia major patients in Jazan region: A hospital-based study. Journal of Family Medicine and Primary Care. 2020;9(1):412-17. https://doi.org/10.4103/jfmpc.jfmpc_1007_19 DOI: https://doi.org/10.4103/jfmpc.jfmpc_1007_19

[32] Saleh KK, Kakey ES. Hematological and biochemical status of βeta-thalassemia major patients in Koya city. ZANCO Journal of Pure and Applied Sciences. 2021;33(5):76-84. http://dx.doi.org/10.21271/ZJPAS.33.5.9 DOI: https://doi.org/10.21271/ZJPAS.33.5.9

[33] Yadgarova N. Thalassemia. Etiology, pathogenesis, clinical picture, diagnosis, treatment. The American Journal of Medical Sciences and Pharmaceutical Research. 2026;8(2):194-99. https://doi.org/10.37547/tajmspr/Volume08Issue02-29 DOI: https://doi.org/10.37547/tajmspr/Volume08Issue02-29

[34] Gowda RY, Gudi JG, Mandolikar RY, Srevatsa K, Kangle RP, Jali SM. A laboratory approach consideration for thrombotic risk assessment in transfusion-dependent beta-thalassemia major utilizing complete blood count cell population data and basic screening hemostatic parameters. Journal of the Scientific Society. 2024;51(3):388-92. https://doi.org/10. 4103/jss.jss_464_23 DOI: https://doi.org/10.4103/jss.jss_464_23

[35] Mohammed MR, Hamoode RH, Al-Mahdawi FKI. Hypoparathyroidism due to iron overload in beta-thalassemia patients. Biomedicine. 2022;42(6):1305-8. https://doi.org/10.51248/.v42i6.2394 DOI: https://doi.org/10.51248/.v42i6.2394

[36] Javad G, Saeid A, Mohammadmehdi N. Thalassemia and immune system dysfunction-review article. International Journal of Current Research. 2011;3(12):105-8.

[37] Bazi A, Shahramian I, Yaghoobi H, Naderi M, Azizi H. The role of immune system in thalassemia major: a narrative review. Journal of Pediatrics Review. 2018;6(2):29-36. https://doi.org/10.5812/jpr.14508 DOI: https://doi.org/10.5812/jpr.14508

[38] Aisyi M, Tumbelaka AR, Munthe BG, Madiyono B. Splenectomy and its relation to non-transfusion-transmitted infection in thalassemic patients. Paediatrica Indonesiana. 2006;46(5-6):134-8. DOI: https://doi.org/10.14238/pi46.3.2006.134-8

[39] Zarina AL, Norazlin KN, Hamidah A, Aziz DA, Zulkifli SZS, Jamal R. Spectrum of infections in splenectomised thalassaemia patients. Medical Journal of Malaysia. 2010;65(4):284-286.

[40] Awadallah S, Al Arrayed K, Bahareth E, Saeed Z. Total antioxidant capacity and ischemia modified albumin in beta thalassemia. Clinical Laboratory. 2013;59(5-6):687-91. https://doi.org/10.7754/clin.lab.2012.120907 DOI: https://doi.org/10.7754/Clin.Lab.2012.120907

[41] Nahi SM, Jabir FA. The correlation of hepcidin with hemoglobin and iron parameters in Iraqi patients with beta-thalassemia majors. Al-Qadisiyah Medical Journal. 2023;19(1):9-14. https://doi.org/10.28922/qmj.2023.19.1.9-14 DOI: https://doi.org/10.28922/qmj.2023.19.1.9-14

[42] Jumaah DA. A Practical study on the relationship between serum iron elevation and liver enzymes plus other factors in patients with beta-thalassemia. SAR Journal of Anatomy and Physiology. 2024;5(3):50-7. https://doi.org/10.36346/sarjap.2024.v05i03.003 DOI: https://doi.org/10.36346/sarjap.2024.v05i03.003

[43] Choudhary F, Rani P, Kotru M, Gomber S, Dewan P, Gupta R, Sikka M, More S. Correlation of T-regulatory cells and iron status in β-thalassemia major patients. Cureus. 2023;15(2):e35084. https://doi.org/10.7759/cureus.35084 DOI: https://doi.org/10.7759/cureus.35084

[44] Ahmad T, Jahanzaib A, Baloch T, Imtiaz H, Iqbal M, Shaban MN, Ali ZZ, Zeshan M, Jahangir A, Mughal FA. Evaluation of serum iron profile in beta thalassemia patients. Insights-Journal of Health and Rehabilitation. 2025;3(4):369-76. DOI: https://doi.org/10.71000/ykgchy44

[45] Sposi NM. Oxidative stress and iron overload in β-thalassemia: an overview. London: IntechOpen Limited; 2020. https://doi.org/10.5772/intechopen.90492 DOI: https://doi.org/10.5772/intechopen.90492

[46] Fibach E, Dana M. Oxidative stress in β-thalassemia. Molecular Diagnosis & Therapy. 2019;23(2):245-61. https://link.springer.com/article/10.1007/s40291-018-0373-5 DOI: https://doi.org/10.1007/s40291-018-0373-5

[47] Bayanzay K, Alzoebie L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. Journal of Blood Medicine. 2016;2016(7):159-69. https://doi.org/10.2147/JBM.S61540 DOI: https://doi.org/10.2147/JBM.S61540

[48] Blanck HM, Pfeiffer CM, Caudill SP, Reyes M, Gunter EW, Imperatore G, van Assendelft OW, Strider S, Dearth T. Serum iron and iron-binding capacity: a round-robin interlaboratory comparison study. Clinical Chemistry. 2003;49(10):1672-75. https://doi.org/10.1373/49.10.1672 DOI: https://doi.org/10.1373/49.10.1672

[49] Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia. Blood. 2019;133(1):51-8. https://doi.org/10.1182/blood-2018-07-815928 DOI: https://doi.org/10.1182/blood-2018-07-815928

[50] Vlachaki E, Venou TM. Iron overload: The achilles heel of β-thalassemia. Transfusion Clinique et Biologique. 2024;31(3):167-73. https://doi.org/10.1016/j.tracli.2024.06.001 DOI: https://doi.org/10.1016/j.tracli.2024.06.001